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ABSTRACT
Breast cancer has emerged as the most common cancer-related mortality among 
women worldwide. Therefore, early cancer detection using biomarkers such as 
microRNA is required. One of microRNAs that has an important role in breast 
cancer development is miR-155. Hsa-miR-155-5p is an oncomiR that is commonly 
dysregulated in breast cancer. This study aims to determine the expression of 
hsa-miR-155-5p in breast cancer patient’s plasma before and after chemotherapy. 
We collected 64 samples from breast cancer patients admitted to Dr. Sardjito 
Hospital in Yogyakarta. RNA from plasma was extracted using RNA Isolation 
Kit miRCURY-Biofluid. cDNA synthesis was performed using cDNA Synthesis 
kit II and quantification of miR-155-5p using ExiLent SYBR Green master mix 
(Exiqon). qRT-PCR results were then analyzed with Livak’s method and compared 
(before and after chemotherapy) to t-test. Expression of miR-155-5p in the breast 
cancer patients’ plasma after chemotherapy was significantly increased (10.59 
times) when compared to before chemotherapy (p = 0.001). We concluded that 
there was upregulated expression of miR-155-5p after chemotherapy than before 
chemotherapy. There has not been a known, relevant pathway between hsa-miR-
155-5p and chemotherapy regimens nor its impact on resistance to chemotherapy.
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